◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ARWR

Arrowhead Pharmaceuticals Inc (ARWR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Arrowhead Pharmaceuticals Inc (ARWR) operates in the BIOTECHNOLOGY industry and is headquartered in Pasadena, United States with about 711 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-09-30, ARWR reported $829M in revenue and ($2M) in net income.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Interactive charts & full statements → Open the ARWR valuation workbench →

ARWR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30	2009-09-30	2008-09-30	2007-09-30	2006-09-30
Total Revenue	$669M	$829M	$4M	$241M	$243M	$138M	$88M	$169M	$16M	$31M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$4M	$1M	$1M	$1M
Gross Profit	—	$829M	($15M)	$228M	$243M	$138M	$88M	$169M	$16M	$31M	$0M	$0M	($4M)	($3M)	($2M)	$0M	($4M)	($5M)	($14M)	($11M)	($7M)
Gross Margin %	—	100.0%	-423.7%	94.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-2076.2%	-993.2%	-1090.8%	9.5%	-698.7%	-139.9%	-1039.8%	-874.8%	-1135.7%
Operating Income (EBIT)	($226M)	$98M	($601M)	($205M)	($179M)	($149M)	($93M)	$61M	($56M)	($37M)	($82M)	($96M)	($53M)	($25M)	($21M)	($10M)	($9M)	($20M)	($35M)	($38M)	($20M)
Operating Margin %	-33.8%	11.9%	-16927.1%	-85.2%	-73.4%	-107.8%	-105.9%	36.2%	-346.5%	-117.8%	-51627.1%	-25124.1%	-30443.6%	-8471.3%	-14358.6%	-3319.5%	-1419.5%	-520.5%	-2685.9%	-3141.4%	-3439.9%
Net Income	($320M)	($2M)	($599M)	($205M)	($176M)	($141M)	($85M)	$68M	($54M)	($34M)	($82M)	($92M)	($59M)	($31M)	($21M)	($3M)	($6M)	($19M)	($27M)	($30M)	($19M)
Net Margin %	-47.8%	-0.2%	-16882.4%	-85.3%	-72.6%	-101.8%	-96.1%	40.3%	-337.3%	-109.5%	-51614.6%	-24068.3%	-33503.0%	-10729.2%	-14383.6%	-1056.6%	-931.2%	-513.8%	-2078.7%	-2477.7%	-3190.3%
EBITDA	—	$165M	($562M)	($176M)	($168M)	($133M)	($87M)	$66M	($51M)	($32M)	($76M)	($94M)	($50M)	($22M)	($19M)	($10M)	($10M)	($19M)	($34M)	($37M)	($20M)
Earnings Per Share (EPS)	$-2.25	$-0.01	$-5.00	$-1.92	$-1.67	$-1.36	$-0.84	$0.69	$-0.65	$-0.47	$-1.34	$-1.60	$-1.25	$-1.30	$-1.90	$-0.44	$-0.90	$-4.27	$-6.91	$-8.35	$-5.95
Shares Outstanding (M)	—	134M	120M	107M	105M	104M	101M	99M	84M	74M	61M	57M	47M	24M	11M	7M	6M	5M	4M	4M	3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$75M	$74M	$264M	$256M	$28M	$543M	$2M	$24M	$0M
Gross Profit	—	$74M	$264M	$256M	$28M	$543M	$2M	($5M)	($5M)
Gross Margin %	—	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-21.3%	—
Operating Income (EBIT)	($170M)	($141M)	$41M	$44M	($166M)	$381M	($161M)	($162M)	($176M)
Operating Margin %	-226.7%	-191.6%	15.5%	17.2%	-596.2%	70.2%	-6456.5%	-687.6%	—
Net Income	($194M)	($133M)	$31M	($24M)	($175M)	$370M	($173M)	($171M)	($171M)
Net Margin %	-258.7%	-180.0%	11.7%	-9.3%	-631.1%	68.3%	-6923.4%	-722.9%	—
EBITDA	—	($107M)	$57M	$64M	($148M)	$397M	($148M)	($153M)	($164M)
Earnings Per Share (EPS)	$-1.36	$-0.93	$0.22	$-0.18	$-1.26	$2.75	$-1.39	$-1.40	$-1.38
Shares Outstanding (M)	—	142M	141M	136M	139M	134M	125M	122M	124M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30	2009-09-30	2008-09-30	2007-09-30	2006-09-30
Cash from Operations (CFO)	($61M)	$180M	($463M)	($154M)	($136M)	$171M	($96M)	$173M	($47M)	($24M)	($64M)	($66M)	($35M)	($19M)	($15M)	($5M)	($8M)	($15M)	($28M)	($24M)	($15M)
Capital Expenditures (CapEx)	$16M	$23M	$141M	$177M	$53M	$24M	$12M	$12M	$1M	$8M	$4M	$2M	$2M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$1M
Free Cash Flow (FCF)	($75M)	$157M	($604M)	($331M)	($189M)	$148M	($108M)	$161M	($49M)	($32M)	($68M)	($68M)	($37M)	($19M)	($16M)	($5M)	($8M)	($15M)	($28M)	($25M)	($16M)
FCF Margin %	-11.2%	18.9%	-17018.3%	-137.3%	-77.7%	106.8%	-122.5%	95.4%	-301.4%	-101.4%	-43129.2%	-17716.8%	-21219.3%	-6659.4%	-10771.1%	-1823.6%	-1242.5%	-407.6%	-2169.2%	-2038.3%	-2641.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($178M)	$84M	$13M	$20M	($155M)	$460M	($146M)	($137M)	($115M)
Capital Expenditures (CapEx)	$4M	$3M	$2M	$7M	$2M	$5M	$8M	$24M	$14M
Free Cash Flow (FCF)	($181M)	$82M	$11M	$13M	($157M)	$455M	($154M)	($162M)	($130M)
FCF Margin %	-241.3%	111.0%	4.3%	5.1%	-565.7%	83.8%	-6151.5%	-684.7%	—
Dividends Paid	—	$42M	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARWR Balance Sheet History

Balance sheet	2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30	2009-09-30	2008-09-30	2007-09-30	2006-09-30
Total Assets	$2.1B	$1.4B	$1.1B	$766M	$692M	$710M	$523M	$350M	$112M	$104M	$128M	$132M	$183M	$37M	$17M	$16M	$12M	$8M	$17M	$30M	$35M
Cash & Cash Equivalents	—	$227M	$103M	$111M	$108M	$184M	$144M	$222M	$30M	$25M	$85M	$81M	$133M	$19M	$3M	$8M	$7M	$2M	$10M	$24M	$28M
Total Liabilities	$1.6B	$882M	$949M	$478M	$274M	$301M	$61M	$106M	$16M	$23M	$33M	$23M	$17M	$12M	$8M	$3M	$4M	$3M	$5M	$3M	$3M
Total Debt (Short + Long-Term)	$984M	$262M	$400M	$11M	$3M	$2M	$1M	$12M	$2M	$3M	$3M	$1M	$1M	$2M	$1M	$2M	$0M	$1M	$2M	$1M	$0M
Total Shareholders' Equity	$466M	$466M	$185M	$271M	$399M	$409M	$462M	$245M	$96M	$81M	$96M	$110M	$167M	$27M	$11M	$13M	$9M	$5M	$12M	$26M	$31M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARWR viewer.

ARWR Metric Deep Dives

Other Companies in BIOTECHNOLOGY

APGE · Apogee Therapeutics, Inc. Common Stock — $10 billion
KRYS · Krystal Biotech Inc — $10 billion
KYMR · Kymera Therapeutics Inc — $10 billion
CYTK · Cytokinetics Inc — $10 billion
PTGX · Protagonist Therapeutics Inc — $9 billion
ABVX · Abivax SA American Depositary Shares — $9 billion
CRNX · Crinetics Pharmaceuticals Inc — $9 billion
IBRX · Immunitybio Inc — $9 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← ARWG All “A” companies ARX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.